PURPOSE: This study measured the impact of previous contact lens wearing schedule on the resolution of signs and contact lens-related symptoms among wearers of lotrafilcon A lenses. METHODS: One hundred forty adapted low Dk daily wear (DW) and 140 adapted low Dk extended wear (EW) subjects were enrolled and examined for 1 year (overall study length is 3 years). All subjects wore lotrafilcon A lenses on a wearing schedule of up to 30 nights continuous wear with monthly replacement of lenses. Examinations were conducted at 1 week, 1, 6, and 12 months. RESULTS: The former EW wearers presented at baseline with significantly higher conjunctival staining and epithelial microcysts (p < 0.05) and lower ocular surface symptoms of end of day dryness than the former DW wearers. There were no significant differences in other ocular signs at baseline for the former DW and EW wearers. After use of lotrafilcon A, clinical signs of limbal, conjunctival redness, and neovascularization were significantly better by the 1-week visit for both groups of wearers. Regardless of former wearing schedule, symptoms of dryness (during and at the end of the day) and photophobia were significantly better after 1 week of lotrafilcon A use. The frequency and severity of symptoms of dryness during the day improved significantly among former low Dk DW and EW wearers within 1 week as did severity of dryness during the day for the former DW wearers, in part as a result of their higher prevalence at baseline in the DW group. Subjects reported redness improved significantly by the 1-month visit. CONCLUSIONS: Continuous wear of high Dk silicone hydrogel lenses resulted in an improvement in ocular redness and neovascularization and dryness symptoms among subjects in this trial, regardless of their previous low Dk lens-wearing schedule. All improvements in signs and symptoms were sustained through 12 months.
PURPOSE: This study measured the impact of previous contact lens wearing schedule on the resolution of signs and contact lens-related symptoms among wearers of lotrafilcon A lenses. METHODS: One hundred forty adapted low Dk daily wear (DW) and 140 adapted low Dk extended wear (EW) subjects were enrolled and examined for 1 year (overall study length is 3 years). All subjects wore lotrafilcon A lenses on a wearing schedule of up to 30 nights continuous wear with monthly replacement of lenses. Examinations were conducted at 1 week, 1, 6, and 12 months. RESULTS: The former EW wearers presented at baseline with significantly higher conjunctival staining and epithelial microcysts (p < 0.05) and lower ocular surface symptoms of end of day dryness than the former DW wearers. There were no significant differences in other ocular signs at baseline for the former DW and EW wearers. After use of lotrafilcon A, clinical signs of limbal, conjunctival redness, and neovascularization were significantly better by the 1-week visit for both groups of wearers. Regardless of former wearing schedule, symptoms of dryness (during and at the end of the day) and photophobia were significantly better after 1 week of lotrafilcon A use. The frequency and severity of symptoms of dryness during the day improved significantly among former low Dk DW and EW wearers within 1 week as did severity of dryness during the day for the former DW wearers, in part as a result of their higher prevalence at baseline in the DW group. Subjects reported redness improved significantly by the 1-month visit. CONCLUSIONS: Continuous wear of high Dk silicone hydrogel lenses resulted in an improvement in ocular redness and neovascularization and dryness symptoms among subjects in this trial, regardless of their previous low Dk lens-wearing schedule. All improvements in signs and symptoms were sustained through 12 months.
Authors: Adam Blacker; G Lynn Mitchell; Mark A Bullimore; Bill Long; Joseph T Barr; Sally M Dillehay; Peter Bergenske; Peter Donshik; Glenda Secor; John Yoakum; Robin L Chalmers Journal: Optom Vis Sci Date: 2009-10 Impact factor: 1.973
Authors: Glenn S Corbin; Linda Bennett; Louis Espejo; Suzanne Carducci; Andrew Sacco; Robert Hannigan; Stuart Schatz Journal: Clin Ophthalmol Date: 2010-02-02